Dark

ARGX
argenx SE
stock NASDAQ ADR

Market Open

Jul 24, 2025 12:43:34 PM EDT

585.04USD+1.673%(+9.62)196,050

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-575.42)0

After-hours

Jul 23, 2025 4:00:30 PM EDT

575.42USD+0.052%(+0.30)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 20, 2022

08:28AM EST The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug Benzinga

02:19AM EST Argenx Announces VYVGART Approval In Japan For Treatment Of Generalized Myasthenia Gravis RTTNews

02:00AM EST argenx Announces VYVGART(tm) Approval in Japan for the Treatment of Generalized Myasthenia Gravis Business Wire

Jan 18, 2022

09:20AM EST What 8 Analyst Ratings Have To Say About argenx Benzinga

08:57AM EST Morgan Stanley Maintains Equal-Weight on argenx, Lowers Price Target to $339 Benzinga

Jan 7, 2022

01:08AM EST Argenx Says On Track For Global Commercial Launch Of VYVGART For Treatment Of Generalized Myasthenia Gravis RTTNews

01:00AM EST argenx Highlights Strategic Priorities for 2022 Business Wire

Jan 3, 2022

01:00AM EST argenx to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc

Dec 21, 2021

10:42AM EST What 8 Analyst Ratings Have To Say About argenx Benzinga

07:12AM EST JMP Securities Maintains Market Outperform on argenx, Raises Price Target to $418 Benzinga

Dec 20, 2021

10:44AM EST Shares of argenx SE (ARGX) are up more than 8% Monday morning. RTTNews

07:46AM EST Raymond James Maintains Strong Buy on argenx, Raises Price Target to $455 Benzinga

07:43AM EST Credit Suisse Maintains Neutral on argenx, Raises Price Target to $340 Benzinga

07:28AM EST The U.S. Food and Drug Administration has granted approval for argenx BV's Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis or gMG in adults who test positive for the anti-acetylcholine receptor (AChR) antibody. RTTNews

07:04AM EST Wells Fargo Maintains Overweight on argenx, Raises Price Target to $395 Benzinga

05:48AM EST A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 4% Benzinga

Dec 19, 2021

12:54PM EST The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week Benzinga

Dec 17, 2021

06:09PM EST -- VYVGART is the first and only FDA-approved neonatal Fc receptor blocker GlobeNewswire Inc

05:14PM EST argenx Press Release Confirms FDA Approval Of Co.'s VYVGART Benzinga

05:09PM EST argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART(tm) (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis Business Wire

04:40PM EST argenx Shares Were Halted Earlier; Now Seeing Report FDA Approves Co.'s Vyvgart For Treatment Of Generalized Myasthenia Gravis Benzinga

07:54AM EST The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx Benzinga

Dec 12, 2021

04:56PM EST The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More Benzinga

Dec 8, 2021

11:23AM EST Analyst Ratings For argenx Benzinga

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 Benzinga

07:27AM EST Wells Fargo Initiates Coverage On argenx with Overweight Rating, Announces Price Target of $390 Benzinga

Dec 2, 2021

12:02PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 30, 2021

04:27PM EST Argenx shares were trading higher amid an upgrade and $354 price target announced by analysts at Piper Sandler. Benzinga

04:09PM EST What 4 Analyst Ratings Have To Say About argenx Benzinga

04:03PM EST Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 Benzinga

Nov 29, 2021

07:29AM EST 10 Biggest Price Target Changes For Monday Benzinga

05:09AM EST Piper Sandler Upgrades argenx to Overweight, Raises Price Target to $354 Benzinga

Nov 10, 2021

01:00AM EST argenx to Present at Upcoming Investor Conferences GlobeNewswire Inc

Oct 29, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021 Benzinga

06:23AM EDT A Peek Into The Markets: US Stock Futures Down; Apple Posts Downbeat Sales Benzinga

05:08AM EDT Guggenheim Upgrades argenx to Buy, Announces $330 Price Target Benzinga

Oct 28, 2021

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

01:00AM EDT U.S. and Japan commercial teams fully staffed ahead of potential launches of efgartigimod in generalized myasthenia gravis (gMG) GlobeNewswire Inc

Oct 21, 2021

01:00AM EDT argenx to Report Third Quarter 2021 Financial Results and Business GlobeNewswire Inc

Oct 19, 2021

12:22PM EDT Analyst Ratings For argenx Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 Benzinga

07:19AM EDT Barclays Upgrades argenx to Overweight Benzinga

Oct 8, 2021

01:00AM EDT -- Additional data from Phase 3 ADAPT trial demonstrate consistent depth of response across first two treatment cycles as measured by minimal symptom expression -- Additional ADAPT data also show consistent disease score improvements by patient subgroup based on affected muscle domain or concomitant medication GlobeNewswire Inc

Oct 7, 2021

12:16PM EDT Expert Ratings For argenx Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 Benzinga

05:02AM EDT Jefferies Initiates Coverage On argenx with Buy Rating, Announces Price Target of $362 Benzinga

Sep 23, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 Benzinga

06:18AM EDT Redburn Partners Upgrades argenx to Buy Benzinga

Sep 7, 2021

12:44PM EDT What 4 Analyst Ratings Have To Say About argenx Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021 Benzinga

06:13AM EDT Morgan Stanley Downgrades argenx to Equal-Weight, Raises Price Target to $351 Benzinga

Sep 3, 2021

01:00AM EDT argenx to Present at Upcoming Investor Conferences GlobeNewswire Inc

Aug 25, 2021

07:30AM EDT The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug Benzinga

01:07AM EDT Argenx Announces Validation Of EMA Application For Efgartigimod In Generalized Myasthenia Gravis RTTNews

01:00AM EDT -- Validation initiates formal evaluation of application which started on August 19, 2021; decision expected mid-2022 -- If approved, efgartigimod will be the first-and-only approved FcRn antagonist in Europe -- Regulatory reviews of efgartigimod for generalized myasthenia gravis currently underway in the U.S., Japan and Europe GlobeNewswire Inc

Aug 4, 2021

01:00AM EDT argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare GlobeNewswire Inc

Aug 3, 2021

12:29PM EDT Expert Ratings for argenx Benzinga

08:24AM EDT Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $332 Benzinga

Jul 30, 2021

08:21AM EDT Argenx SE Earlier Reported H1 2021 Sales $470.4M Up From $24.7M YoY Benzinga

Jul 29, 2021

07:24AM EDT Recap: argenx Q2 Earnings Benzinga

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

01:00AM EDT - Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022 GlobeNewswire Inc

Jul 23, 2021

02:58PM EDT Analyst Ratings For argenx Benzinga

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021 Benzinga

07:25AM EDT Deutsche Bank Initiates Coverage On argenx with Hold Rating Benzinga

Jul 22, 2021

12:24PM EDT Where argenx Stands With Analysts Benzinga

08:41AM EDT Wedbush Maintains Outperform on argenx, Raises Price Target to $362 Benzinga

01:00AM EDT argenx to Report Half Year 2021 Financial Results and Second GlobeNewswire Inc

Jul 14, 2021

01:00AM EDT argenx to Host Virtual R&D Day on July 20, 2021 GlobeNewswire Inc

Jun 18, 2021

12:47PM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021 Benzinga

11:56AM EDT Where argenx Stands With Analysts Benzinga

07:47AM EDT UBS Initiates Coverage On argenx with Buy Rating, Announces Price Target of $390 Benzinga

Jun 16, 2021

06:30PM EDT Results from ADAPTshowed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures ingeneralized myasthenia gravis (gMG) GlobeNewswire Inc

Jun 8, 2021

09:26AM EDT Wedbush Maintains Outperform on argenx, Lowers Price Target to $344 Benzinga

09:16AM EDT Baird Maintains Outperform on argenx, Lowers Price Target to $333 Benzinga

Jun 7, 2021

08:31AM EDT Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab Benzinga

01:43AM EDT argenx SE (ARGX), an immunology company, announced Monday that it will regain worldwide rights to its anti-CD70 antibody cusatuzumab from Cilag GmbH International, part of Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). RTTNews

01:09AM EDT Argenx To Regain Worldwide Rights To Its Anti-CD70 Antibody Cusatuzumab From Cilag GmbH RTTNews

01:00AM EDT argenx to regain global rights to cusatuzumab GlobeNewswire Inc

Jun 1, 2021

04:01AM EDT argenx Appoints Karl Gubitz as Chief Financial Officer GlobeNewswire Inc

01:00AM EDT argenx to Present at Upcoming Investor Conferences GlobeNewswire Inc

May 18, 2021

09:12AM EDT Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $324 Benzinga

May 14, 2021

07:07AM EDT Recap: argenx Q1 Earnings Benzinga

04:03AM EDT Earnings Scheduled For May 14, 2021 Benzinga

01:45AM EDT Argenx Q1 Loss/Shr $0.81 Vs Loss $2.06 Last Year RTTNews

01:00AM EDT Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japans Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG) GlobeNewswire Inc

May 13, 2021

12:45PM EDT argenx's Earnings Outlook Benzinga

May 11, 2021

05:00AM EDT argenx announces results of Annual General Meeting of Shareholders GlobeNewswire Inc

May 10, 2021

10:16AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2021 Benzinga

06:22AM EDT HC Wainwright & Co. Upgrades argenx to Buy, Raises Price Target to $400 Benzinga

May 7, 2021

01:00AM EDT argenx to Report First Quarter 2021 Financial Results and Business GlobeNewswire Inc

Apr 28, 2021

01:00AM EDT argenx Management to Present at Upcoming Virtual Investor Conferences GlobeNewswire Inc

Apr 19, 2021

09:19AM EDT Morgan Stanley Maintains Overweight on argenx, Lowers Price Target to $321 Benzinga

Mar 30, 2021

04:00PM EDT argenx announces Annual General Meeting of Shareholders on May 11, GlobeNewswire Inc

Mar 8, 2021

10:40AM EST Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $326 Benzinga

Mar 5, 2021

07:40AM EST 10 Biggest Price Target Changes For Friday Benzinga

06:12AM EST HC Wainwright & Co. Maintains Neutral on argenx, Raises Price Target to $320 Benzinga

Mar 4, 2021

07:16AM EST argenx: Q4 Earnings Insights Benzinga

04:07AM EST Earnings Scheduled For March 4, 2021 Benzinga

01:00AM EST - Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG) GlobeNewswire Inc

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

05:40AM EST Argenx's Efgartigimod US Application In Neuromuscular Disorder Accepted For Review Benzinga

02:00AM EST argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for GlobeNewswire Inc

Feb 25, 2021

01:00AM EST argenx to Report Full Year 2020 Financial Results and Fourth GlobeNewswire Inc

Feb 18, 2021

11:49AM EST Cowen & Co. Maintains Outperform on argenx, Raises Price Target to $430 Benzinga

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 5, 2021

04:01PM EST argenx announces closing of global offering GlobeNewswire Inc

Feb 4, 2021

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

01:00AM EST argenx announces full exercise of underwriters GlobeNewswire Inc

Feb 3, 2021

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

05:45AM EST argenx Raised $1B in Gross Proceeds in Global Offering; Sold 1.6M ADS's @$320/ADS Benzinga

Feb 2, 2021

10:15PM EST argenx raises $1.0 billion in gross proceeds in a global offering GlobeNewswire Inc

12:42PM EST Argenx shares were trading lower after the company announced a $750 million global offering. Piper Sandler also downgraded the stock from Overweight to Neutral. Benzinga

11:45AM EST Wells Fargo Maintains Equal-Weight on argenx, Raises Price Target to $326 Benzinga

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2021 Benzinga

09:42AM EST Argenx Says Not Aware Of Any Elevation Of Cholesterol Markers Related To Treatment With Efgartigimod RTTNews

09:40AM EST argenx Offers Statement Related To Efgartigimod: 'No observed elevation of cholesterol markers related to treatment with efgartigimod' Benzinga

09:37AM EST -No observed elevation of cholesterol markers related to treatment with efgartigimod GlobeNewswire Inc

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

05:58AM EST Piper Sandler Downgrades argenx to Neutral, Raises Price Target to $303 Benzinga

Feb 1, 2021

04:02PM EST Argenx Announces Launch Of $750M Proposed Global Offering Benzinga

04:01PM EST argenx announces launch of proposed global offering GlobeNewswire Inc

01:00AM EST argenx Announces GO Decision GlobeNewswire Inc

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 22, 2021

07:22AM EST The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

01:00AM EST argenx Announces 2021 Corporate Priorities and Highlights Recent GlobeNewswire Inc

Jan 6, 2021

04:01PM EST argenx and Zai Lab Announce Strategic Collaboration for GlobeNewswire Inc

Jan 4, 2021

01:00AM EST argenx to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc

Dec 16, 2020

12:19PM EST Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $311 Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 2, 2020

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 23, 2020

01:32AM EST argenx (ARGX) said that it agreed to acquire a U.S. Food and Drug Administration Priority Review Voucher or PRV from Bayer Healthcare Pharmaceuticals Inc for $98 million. RTTNews

01:06AM EST Argenx Agrees To Buy FDA Priority Review Voucher From Bayer Healthcare Pharmaceuticals For $98 Mln RTTNews

01:00AM EST argenx Enters Into Agreement To Acquire Priority Review Voucher GlobeNewswire Inc

Nov 17, 2020

07:00AM EST argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia PR Newswire

Nov 11, 2020

07:47AM EST Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $295 Benzinga

Nov 9, 2020

01:00AM EST November 9, 2020 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that management will participate in several upcoming investor conferences: GlobeNewswire Inc

Nov 4, 2020

05:56AM EST What's moving these stocks in the pre-market hours today? RTTNews

Oct 23, 2020

09:11AM EDT Truist Securities Maintains Buy on argenx, Raises Price Target to $275 Benzinga

06:43AM EDT HC Wainwright & Co. Maintains Neutral on argenx, Lowers Price Target to $265 Benzinga

Oct 22, 2020

07:38AM EDT Argenx Earlier Reported Q3 EPS $(3.96) Misses $(2.81) Estimate, Sales $8.97M Miss $16.85M Estimate Benzinga

07:17AM EDT Recap: argenx Q3 Earnings Benzinga

04:38AM EDT Earnings Scheduled For October 22, 2020 Benzinga

01:00AM EDT - Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted toU.S. Food and Drug Administration(FDA) by end of 2020 - GlobeNewswire Inc

Oct 15, 2020

01:00AM EDT argenx to Report Third Quarter 2020 Financial Results and Business GlobeNewswire Inc

Oct 6, 2020

12:30PM EDT B of A Securities Maintains Buy on argenx, Raises Price Target to $298 Benzinga

05:26AM EDT argenx Announced New Partnerships With Chugai and the Clayton Foundation for Research to Provide Access to Innovative Antibody Engineering Technologies Benzinga

05:22AM EDT Halozyme Announces Expansion of Collaboration and License Agreement With argenx for ENHANZE Technology Benzinga

02:00AM EDT -- New partnerships with Chugai and the Clayton Foundation for Research provide access to innovative antibody engineering technologies -- Extension of Halozyme collaboration supports long-term commitment to subcutaneous delivery options for patients GlobeNewswire Inc

Oct 5, 2020

08:47AM EDT JMP Securities Maintains Outperform on argenx, Raises Price Target to $271 Benzinga

01:14AM EDT Argenx Presents New Data From Pivotal Phase 3 ADAPT Trial Evaluating Efgartigimod RTTNews

01:00AM EDT -- New data consistent with positive topline results showing rapid and clinically meaningful responses to efgartigimod and safety profile comparable to placebo -- Biologics License Application on track to be submitted to U.S. Food and Drug Administration by end of 2020 GlobeNewswire Inc

Sep 30, 2020

08:33AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

08:17AM EDT Piper Sandler Maintains Overweight on argenx, Raises Price Target to $300 Benzinga

Sep 2, 2020

01:00AM EDT September 2, 2020Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences: GlobeNewswire Inc

Aug 25, 2020

09:35AM EDT Benzinga's Top Upgrades, Downgrades For August 25, 2020 Benzinga

07:02AM EDT Raymond James Initiates Coverage On argenx with Outperform Rating, Announces Price Target of $257 Benzinga

Aug 19, 2020

10:08AM EDT Argenx Shares Lower; Hearing Evercore Downgrades Co Benzinga

Aug 10, 2020

08:39AM EDT 10 Biggest Price Target Changes For Monday Benzinga

08:26AM EDT Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $281 Benzinga

Aug 4, 2020

01:00AM EDT argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual GlobeNewswire Inc

Jul 30, 2020

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

01:00AM EDT argenx reports half year 2020 financial results and provides GlobeNewswire Inc

Jul 29, 2020

01:47PM EDT Earnings Preview: argenx Benzinga

09:38AM EDT Benzinga's Top Upgrades, Downgrades For July 29, 2020 Benzinga

06:05AM EDT HC Wainwright & Co. Initiates Coverage On argenx with Neutral Rating, Announces Price Target of $272 Benzinga

document.getElementById("QLCWLC").onerror = function(){this.style.display='none';}; .dark-mode .PWd8bX{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .PWd8bX{ color: #333333; background-color: white; border: 2px solid #333333; }ARGXargenx SEstock NASDAQ ADR

ARGX
argenx SE
stock NASDAQ ADR